Development of functionally selective, small molecule agonists at kappa opioid receptors

Journal of Biological Chemistry

Volumn 288, Issue 51, 2013, Pages 36703-36716

  Zhou, Lei ^a   Lovell, Kimberly M ^a   Frankowski, Kevin J ^b,c   Slauson, Stephen R ^c   Phillips, Angela M ^a   Streicher, John M ^a,b   Stahl, Edward ^a   Schmid, Cullen L ^a   Hodde, Peter ^c   Madoux, Franck ^c   Cameron, Michael D ^a   Prisinzano, Thomas E ^b   Aubé, Jeffrey ^b,c   Bohn, Laura M ^a  

^a Departments of Molecular Therapeutics and Neuroscience   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; DRUG PRODUCTS; MOLECULES;

KAPPA OPIOID RECEPTOR; PAIN PERCEPTION; PHYSIOLOGICAL EFFECTS; SIGNALING CASCADES; SIGNALING PATHWAYS; SMALL MOLECULES; STRESS RESPONSE; THERAPEUTIC POTENTIALS;

PROTEINS;

ANALGESIC AGENT; BETA ARRESTIN 2; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOQUINOLINONE DERIVATIVE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; AREA UNDER THE CURVE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; ENZYME ACTIVATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PAIN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ARRESTIN; BRAIN; DRUG DISCOVERY; DYSPHORIA; ERK; G PROTEIN-COUPLED RECEPTORS (GPCR); KAPPA OPIOID RECEPTOR; OPIATE OPIOID; PAIN;

ANIMALS; ARRESTINS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DISCOVERY; GTP-BINDING PROTEINS; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; QUINOLONES; RECEPTORS, OPIOID, KAPPA; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84891363547     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.504381     Document Type: Article

References (64)

1. Cox, B. M. (2013) Recent developments in the study of opioid receptors. Mol. Pharmacol. 83, 723-728
2. Chavkin, C., James, I. F., and Goldstein, A. (1982) Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215, 413-415
3. Mansour, A., Fox, C. A., Burke, S., Meng, F., Thompson, R. C., Akil, H., and Watson, S. J. (1994) Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J. Comp. Neurol. 350, 412-438
4. Minami, M., and Satoh, M. (1995) Molecular biology of the opioid receptors: Structures, functions and distributions. Neurosci. Res. 23, 121-145
5. Prather, P. L., McGinn, T. M., Claude, P. A., Liu-Chen, L. Y., Loh, H. H., and Law, P. Y. (1995) Properties of a kappa-opioid receptor expressed in CHO cells: interaction with multiple G-proteins is not specific for any individual Gα subunit and is similar to that of other opioid receptors. Brain Res. Mol. Brain Res. 29, 336-346
6. Lawrence, D. M., and Bidlack, J. M. (1993) The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. J. Pharmacol. Exp. Ther. 266, 1678-1683
7. + channel by a G protein-linked mechanism: Coexpression in Xenopus oocytes. Mol. Pharmacol. 47, 1035-1040
8. Macdonald, R. L., and Werz, M. A. (1986) DynorphinAdecreases voltagedependent calcium conductance of mouse dorsal root ganglion neurones. J. Physiol. 377, 237-249
9. H] ethylketocyclazocine receptor binding and ketocyclazocine analgesia. Proc. Natl. Acad. Sci. U.S.A. 77, 3691-3694
10. Vonvoigtlander, P. F., Lahti, R. A., and Ludens, J. H. (1983) U-50,488: A selective and structurally novel non-Mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 224, 7-12
11. Dykstra, L. A., Gmerek, D. E., Winger, G., and Woods, J. H. (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J. Pharmacol. Exp. Ther. 242, 413-420
12. Millan, M. J., Członkowski, A., Lipkowski, A., and Herz, A. (1989) Kappaopioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. J. Pharmacol. Exp. Ther. 251, 342-350
13. Simonin, F., Valverde, O., Smadja, C., Slowe, S., Kitchen, I., Dierich, A., Le Meur, M., Roques, B. P., Maldonado, R., and Kieffer, B. L. (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 17, 886-897
14. Goicoechea, C., Ormazábal, M. J., Abalo, R., Alfaro, M. J., and Martín, M. I. (1999) Calcitonin reverts pertussis toxin blockade of the opioid analgesia in mice. Neurosci. Lett. 273, 175-178
15. 2+ channels in pertussis toxin induced antagonism of U50,488H analgesia and hypothermia. Brain Res. 946, 191-197
16. Raehal, K. M., and Bohn, L. M. (2005) Mu opioid receptor regulation and opiate responsiveness. AAPS J. 7, E587-E591
17. Pfeiffer, A., Brantl, V., Herz, A., and Emrich, H. M. (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233, 774-776
18. Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., and Chavkin, C. (2008) The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J. Neurosci. 28, 407-414
19. Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., and Rothman, R. B. (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. U.S.A. 99, 11934-11939
20. Knoll, A. T., and Carlezon, W. A., Jr. (2010) Dynorphin, stress, and depression. Brain Res. 1314, 56-73
21. Bohn, L. M. (2009) in Functional Selectivity of G Protein-coupled Receptor Ligands (Neve, K. A., ed) 1st Ed., pp. 71-85, Humana Press Inc., Totowa, NJ
22. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13
23. Reiter, E., Ahn, S., Shukla, A. K., and Lefkowitz, R. J. (2012) Molecular mechanism ofβ-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52, 179-197
24. Luttrell, D. K., and Luttrell, L. M. (2003) Signaling in time and space: G protein-coupled receptors and mitogen-activated protein kinases. Assay Drug Dev. Technol. 1, 327-338
25. Schmid, C. L., and Bohn, L. M. (2009) Physiological and pharmacological implications of β-arrestin regulation. Pharmacol. Ther. 121, 285-293
26. Shenoy, S. K., and Lefkowitz, R. J. (2011) β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 32, 521-533
27. Lefkowitz, R. J., and Shenoy, S. K. (2005) Transduction of receptor signals by β-arrestins. Science 308, 512-517
28. McLennan, G. P., Kiss, A., Miyatake, M., Belcheva, M. M., Chambers, K. T., Pozek, J. J., Mohabbat, Y., Moyer, R. A., Bohn, L. M., and Coscia, C. J. (2008) Kappa opioids promote the proliferation of astrocytes via GGβγ and β-arrestin 2-dependent MAPK-mediated pathways. J. Neurochem. 107, 1753-1765
29. Bruchas, M. R., Macey, T. A., Lowe, J. D., and Chavkin, C. (2006) Kappa opioid receptor activation of p38MAPKis GRK3- and arrestin-dependent in neurons and astrocytes. J. Biol. Chem. 281, 18081-18089
30. Bruchas, M. R., Land, B. B., Aita, M., Xu, M., Barot, S. K., Li, S., and Chavkin, C. (2007) Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J. Neurosci. 27, 11614-11623
31. Bohn, L. M., Belcheva, M. M., and Coscia, C. J. (2000) Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J. Neurochem. 74, 564-573
32. Belcheva, M. M., Clark, A. L., Haas, P. D., Serna, J. S., Hahn, J. W., Kiss, A., and Coscia, C. J. (2005) Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes. J. Biol. Chem. 280, 27662-27669
33. Bruchas, M. R., Xu, M., and Chavkin, C. (2008) Repeated swim stress induces kappa opioid-mediated activation of extracellular signal-regulated kinase 1/2. Neuroreport 19, 1417-1422
34. Bruchas, M. R., and Chavkin, C. (2010) Kinase cascades and ligand-directed signaling at the kappa opioid receptor.Psychopharmacology 210, 137-147
35. Hedrick, M. P., Gosalia, P., Frankowski, K., Shi, S., Prisinzano, T. E., Schoenen, F., Aube, J., Su, Y., Vasile, S., Sergienko, E., Gray, W., Hariharan, S., Ghosh, P., Milan, L., Heynen-Genel, S., Chung, T. D. Y., Dad, S., Caron, M., Bohn, L. M., and Barak, L. S. (2010) Probe Reports from the NIH Molecular Libraries Program, Bethesda, MD
36. Frankowski, K. J., Hedrick, M. P., Gosalia, P., Li, K., Shi, S., Whipple, D., Ghosh, P., Prisinzano, T. E., Schoenen, F. J., Su, Y., Vasile, S., Sergienko, E., Gray, W., Hariharan, S., Milan, L., Heynen-Genel, S., Mangravita-Novo, A., Vicchiarelli, M., Smith, L. H., Streicher, J. M., Caron, M. G., Barak, L. S., Bohn, L. M., Chung, T. D., and Aubé, J. (2012) Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a HTS and hit refinement strategy. ACS Chem. Neurosci. 3, 221-236
37. Frankowski, K. J., Hirt, E. E., Zeng, Y., Neuenswander, B., Fowler, D., Schoenen, F., and Aubé, J. (2007) Synthesis ofN-alkyl- octahydroisoquinolin-1-one-8-carboxamide libraries using a tandem Diels-Alder/acylation sequence. J. Comb. Chem. 9, 1188-1192
38. Frankowski, K. J., Ghosh, P., Setola, V., Tran, T. B., Roth, B. L., and Aubé, J. (2010) N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a novel class of selective, nonbasic, nitrogen-containing kappa-opioid receptor ligands. ACS Med. Chem. Lett. 1, 189-193
39. 3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur. J. Pharmacol. 109, 281-284
40. Jones, R. M., and Portoghese, P. S. (2000) 5″-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur. J. Pharmacol. 396, 49-52
41. Thomas, J. B., Atkinson, R. N., Rothman, R. B., Fix, S. E., Mascarella, S. W., Vinson, N. A., Xu, H., Dersch, C. M., Lu, Y., Cantrell, B. E., Zimmerman, D. M., and Carroll, F. I. (2001) Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly po-tent and selective opioid kappa receptor antagonist activity. J. Med. Chem. 44, 2687-2690
42. Schmid, C. L., Streicher, J. M., Groer, C. E., Munro, T. A., Zhou, L., and Bohn, L. M. (2013) Functional selectivity of 6″-guanidinonaltrindole (6″- GNTI) at kappa opioid receptors in striatal neurons. J. Biol. Chem. 288, 22387-22398
43. Ananthan, S., Saini, S. K., Dersch, C. M., Xu, H., McGlinchey, N., Giuvelis, D., Bilsky, E. J., and Rothman, R. B. (2012) 14-Alkoxy- and 14-acyloxypyridomorphinans: mu agonist/delta antagonist opioid analgesics with diminished tolerance and dependence side effects. J. Med. Chem. 55, 8350-8363
44. Breivogel, C. S., Walker, J. M., Huang, S. M., Roy, M. B., and Childers, S. R. (2004) Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology 47, 81-91
45. McGuinness, R. (2007) Impedance-based cellular assay technologies: Recent advances, future promise. Curr. Opin. Pharmacol. 7, 535-540
46. Robinson, J., Smith, A., Sturchler, E., Tabrizifard, S., Kamenecka, T., and McDonald, P. (2013) Development of a high-throughput screening-compatible cell-based functional assay to identify small molecule probes of the galanin 3 receptor (GalR3). Assay Drug Dev. Technol. 10.1089/adt.2013.526
47. Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J., and Caron, M. G. (2000) Mu-opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature 408, 720-723
48. Valko, K., My Du, C., Bevan, C., Reynolds, D. P., and Abraham, M. H. (2001) Rapid method for the estimation of octanol/water partition coefficient (log P(oct)) from gradient RP-HPLC retention and a hydrogen bond acidity term ( ζ(2)(H)). Curr. Med. Chem. 8, 1137-1146
49. Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., and Lin, F. T. (1999) Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286, 2495-2498
50. Raehal, K. M., Schmid, C. L., Medvedev, I. O., Gainetdinov, R. R., Premont, R. T., and Bohn, L. M. (2009) Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. Drug Alcohol Depend. 104, 187-196
51. Black, J. W., and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond B Biol. Sci. 220, 141-162
52. Kenakin, T., and Christopoulos, A. (2013) Signalling bias in new drug discovery: Detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216
53. Evans B.A., Broxton N., Merlin J., Sato M., Hutchinson D.S., Christopoulos A., Summers R.J. (2011) .Quantification of functional selectivity at the human α(1A)-adrenoceptor Mol. Pharmacol 79,298-307
54. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., and Novick, S. (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193-203
55. Bohn, L. M., and McDonald, P. H. (2010) Seeking ligand bias: Assessing GPCR coupling to beta-arrestins for drug discovery. Drug Discov. Today Technol. 7, e37-e42
56. Barak, L. S., Ferguson, S. S., Zhang, J., and Caron, M. G. (1997) A β-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J. Biol. Chem. 272, 27497-27500
57. Barak, L. S., Warabi, K., Feng, X., Caron, M. G., and Kwatra, M. M. (1999) Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and β-Arrestin 2 during homologous desensitization of the substance P receptor. J. Biol. Chem. 274, 7565-7569
58. Peters, M. F., and Scott, C. W. (2009) Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J. Biomol. Screen. 14, 246-255
59. McLaughlin, J. P., Myers, L. C., Zarek, P. E., Caron, M. G., Lefkowitz, R. J., Czyzyk, T. A., Pintar, J. E., and Chavkin, C. (2004) Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J. Biol. Chem. 279, 1810-1818
60. Mogil, J. S., Wilson, S. G., Chesler, E. J., Rankin, A. L., Nemmani, K. V., Lariviere, W. R., Groce, M. K., Wallace, M. R., Kaplan, L., Staud, R., Ness, T. J., Glover, T. L., Stankova, M., Mayorov, A., Hruby, V. J., Grisel, J. E., and Fillingim, R. B. (2003) The melanocortin-1 receptor gene mediates femalespecific mechanisms of analgesia in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 100, 4867-4872
61. Chavkin, C. (2011) The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology 36, 369-370
62. Rives, M. L., Rossillo, M., Liu-Chen, L. Y., and Javitch, J. A. (2012) 6″- Guanidinonaltrindole (6″-GNTI) is a G protein-biased kappa-opioid receptor agonist that inhibits arrestin recruitment. J. Biol. Chem. 287, 27050-27054
63. Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X. P., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. D., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485, 327-332
64. Ahn, S., Shenoy, S. K., Wei, H., and Lefkowitz, R. J. (2004) Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J. Biol. Chem. 279, 35518-35525